Breast cancer cells were treated with recombinant mouse (mFGF2) or human (hFGF2) FGF2 protein for 72 h and assessed for changes in stem-like ALDHhiCD44+ phenotype via flow cytometry. This evidence concerns the gene FGF2 and breast cancer.